Postdoctoral Fellow (T Cell Engineering)

Our laboratory translates discoveries in tumor biology into antibody- and T-cell-based therapies by investigating how antigen biology, epitope geometry, and receptor architecture shape immune cell function. To address the scarcity of tumor-selective cell surface targets, our laboratory has pioneered glypican research, helping to establish GPC1, GPC2, and GPC3 as regulators of WNT signaling and therapeutic targets in pancreatic, pediatric, and liver cancers.

We have also built one of the largest repertoires of single-domain antibodies to advance drug discovery. As such, we develop CAR T cells for difficult-to-treat cancers, with several candidates advancing to clinical trials, including hYP7, which targets GPC3, and hYP218, which targets mesothelin.

Prospective postdoctoral fellows will receive training in antibody and T-cell receptor engineering and contribute to the development of next-generation CAR T cell therapies in our highly-collaborative research environment. The selected candidate will lead an independent research project focused on advancing CAR T cell technologies using novel TCR scaffolds, clinically relevant factors, and genome editing.

Prospective candidates should have a Ph.D. or M.D./Ph.D. as well as a have a strong publication record in cancer immunology and cancer biology. Highly-motivated candidates interested in innovative, high-impact basic and translational research are encouraged to apply. A research background in immunology or cancer biology is required. Experience with CRISPR and/or base editing, organoid models, or animal models of cancer is a plus.

U.S. citizens and permanent residents are eligible to apply. NIH welcomes foreign nationals with the exception of individuals from this list. This position is subject to a background investigation. The NIH is dedicated to building a diverse community in its training and employment programs.